Drug Profile
Zamaglutenase - Takeda
Alternative Names: Kuma-062; KumaMax; PvP-001; PvP-002; Synthetic enzymes - PvP Biologics; TAK-062Latest Information Update: 08 Aug 2022
Price :
$50
*
At a glance
- Originator University of Washington
- Developer PvP Biologics
- Class Anti-inflammatories; Digestion aids; Enzymes; Peptide hydrolases; Proteins; Recombinant proteins
- Mechanism of Action Gliadin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease
Most Recent Events
- 30 Jun 2022 Phase-II clinical trials in Coeliac disease (In adolescents, In adults, In the elderly) in USA (PO) (NCT05353985)
- 11 Nov 2021 Zamaglutenase is still in phase I trials for Coeliac disease in USA
- 28 Jul 2021 No recent reports of development identified for phase-I development in Coeliac disease in USA (PO)